Top-News
Pharmazeutika Australien

Alterity Therapeutics ADR News

Aktie
WKN:  A3D4GD ISIN:  US02155X2053 US-Symbol:  ATHE
1,925 €
-0,005 €
-0,26%
20:42:46 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
4,01 Mio.
Marktkapitalisierung *
7,64 Mio. €
Streubesitz
-
Faktor
0.00166667
Originalaktie
AU0000043945
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 09.01.2023

Alterity Therapeutics ADR News

31.01.23 - PR Newswire
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report PR Newswire
09.01.23 - PR Newswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy PR Newswire
06.01.23 - PR Newswire
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) PR Newswire
03.01.23 - PR Newswire
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum PR Newswire
29.12.22 - PR Newswire
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office PR Newswire
28.10.22 - PR Newswire
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report PR Newswire
26.10.22 - PR Newswire
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting PR Newswire
13.10.22 - PR Newswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy PR Newswire
26.09.22 - PR Newswire
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and ...
20.09.22 - PR Newswire
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy PR Newswire
25.08.22 - PR Newswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe PR Newswire
22.07.22 - PR Newswire
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report PR Newswire
06.07.22 - PR Newswire
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy PR Newswire
23.06.22 - PR Newswire
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy PR Newswire
02.06.22 - PR Newswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy PR Newswire
27.04.22 - PR Newswire
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom PR Newswire
06.04.22 - PR Newswire
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting PR Newswire
07.03.22 - PR Newswire
Alterity Therapeutics to Present at the 34th Annual Roth Conference
Alterity Therapeutics to Present at the 34th Annual Roth Conference PR Newswire
28.01.22 - PR Newswire
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease Study ...
27.01.22 - PR Newswire
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report PR Newswire

Newssuche

Videos

newspaper
08:55 Uhr +2,22%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »